On September 2, 2020 Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, reported that Dr. James A. Hayward, Chief Executive Officer, will participate virtually in the H.C Wainwright 22nd Annual Global Investment Conference on September 15 at 2:30 p.m. ET (Press release, Applied DNA Sciences, SEP 2, 2020, https://adnas.com/applied-dna-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-on-september-15/ [SID1234564282]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Dr. Hayward’s presentation will be available in the "IR Calendar" section on the Investor Relations page of the Applied DNA website at adnas.com.